TG Therapeutics | TGTX - Gross Profit On Sales


TG Therapeutics reported $122.21M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 702.61M
Cash and Equivalent USD 278.86M
Cost of Sales USD 18.94M
Current Assets USD 663.96M
Current Liabilities USD 171.89M
Debt USD 8.98M
EBIT USD 34.84M
EBITDA USD 12.28M
Employees 338
EPS Earnings Per Share USD 0.17
Equity Capital and Reserves USD 276.43M
Gross Profit on Sales USD 122.21M
Interest Expense on Debt USD 6.72M
Loan Capital USD 245.04M
Market Capitalization USD 4.97B
Net Income USD 28.19M
Operating Expenses USD 106.31M
Operating Profit USD 34.84M
Ordinary Share Capital USD 158.03M
PE Price to Earnings USD 88.77
Pre-Tax Profit USD 30.92M
Sales Revenues USD 141.1M
Selling and Administration Expenses USD 12.04M
Stock USD 155.2M
Trade Creditors USD 134.02M
Trade Debtors USD 231.52M

Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Alaunos Therapeutics USD -1127000 1.11M Sep/2024
Amgen USD 6.17B 624M Jun/2025
Ardelyx USD 82.84M 15.02M Jun/2025
Arrowhead Research USD 27.77M 514.94M Jun/2025
Bayer EUR 6.38B 1.74B Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
J&J USD 14.6B 816M Mar/2025
Novartis USD 11.51B 1.12B Jun/2025
PTC Therapeutics USD 163.39M 999.84M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
TG Therapeutics USD 122.21M 16.9M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025